ClinicalTrials.gov
ClinicalTrials.gov Menu

Angiotensin Converting Enzyme Inhibitors and Periprocedural Myocardial Infarction

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02054390
Recruitment Status : Completed
First Posted : February 4, 2014
Last Update Posted : June 20, 2014
Sponsor:
Information provided by (Responsible Party):
Özgür Ulaş Özcan, Ankara University

Study Description
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Metabolic syndrome (MS) has been reported as a risk for cardiovascular events. The aim of the present cohort study is to investigate whether ACEi therapy reduces the rate of periprocedural myocardial injury (PPMI) after elective percutaneous coronary intervention (PCI) among patients with metabolic syndrome.

Condition or disease
Metabolic Syndrome Coronary Artery Disease

Study Design
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type : Observational
Actual Enrollment : 459 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Angiotensin Converting Enzyme Inhibitor Therapy and Periprocedural Myocardial Infarction in Patients With Metabolic Syndrome
Study Start Date : February 2014
Actual Primary Completion Date : June 2014
Actual Study Completion Date : June 2014

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Groups and Cohorts
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information


Outcome Measures
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Periprocedural myocardial injury (MI) [ Time Frame: 24 hours after (percutaneous coroary intervention) PCI ]
    Periprocedural MI was defined as cardiac Troponin I release [5 times ULN] 24 hours after percutaneous coronary intervention


Secondary Outcome Measures :
  1. Periprocedural myonecrosis [ Time Frame: 24 hours after PCI ]
    Peri-procedural myonecrosis was defined as troponin I release of >1×ULN 24 hours after the intervention.


Other Outcome Measures:
  1. inflammatory marker [ Time Frame: 24 hours after PCI ]
    high sensitive C-reactive protein measurement 24 hours after PCI


Eligibility Criteria
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Metabolic syndorme (MS) was defined as the presence of 3 or more of these components:

  1. high fasting glucose (fasting serum glucose ≥100 mg/dl or drug treatment for elevated blood glucose)
  2. abdominal obesity (given as waist circumference >102 cm in men and >88 cm in women)
  3. high blood pressure (>130/>85 mmHg or drug treatment for hypertension)
  4. hypertriglyceridemia (serum triglycerides ≥150 mg/dl)
  5. low high-density lipoprotein (HDL) cholesterol (<40 mg/dl in men and <50 mg/dl in women).
Criteria

Inclusion Criteria:

  1. metabolic syndrome
  2. elective percutaneous coronary intervention with angiographically successful stent implantation

Exclusion Criteria:

  1. acute coronary events
  2. renal failure
  3. needed the use of IV glycoprotein IIb/IIIa receptor inhibitors were excluded
  4. left main coronary artery disease
  5. chronic total occlusion
  6. high levels of baseline CKMB or troponin
  7. any contraindication of aspirin, clopidogrel or ACEi treatment
Contacts and Locations
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02054390


Locations
Turkey
Ankara University School Of Medicine, Department of Cardiology
Ankara, Turkey, 06230
Sponsors and Collaborators
Ankara University
More Information
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party: Özgür Ulaş Özcan, MD, Ankara University
ClinicalTrials.gov Identifier: NCT02054390     History of Changes
Other Study ID Numbers: ACEmetsend
First Posted: February 4, 2014    Key Record Dates
Last Update Posted: June 20, 2014
Last Verified: June 2014

Keywords provided by Özgür Ulaş Özcan, Ankara University:
Angiotensin converting enzyme inhibitor
inflammation
metabolic syndrome
 myonecrosis
percutaneous coronary intervention
periprocedural myocardial injury

Additional relevant MeSH terms:
Syndrome
Infarction
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Myocardial Infarction
Metabolic Syndrome X
Disease
Pathologic Processes
Ischemia
Necrosis
Heart Diseases
 Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Insulin Resistance
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases
Enzyme Inhibitors
Angiotensin-Converting Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Protease Inhibitors